{"id":"biguanides-thiazolidinediones","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Fluid retention / edema"},{"rate":null,"effect":"Gastrointestinal disturbance (nausea, diarrhea)"},{"rate":null,"effect":"Lactic acidosis risk (biguanide component)"},{"rate":null,"effect":"Heart failure exacerbation"}]},"_chembl":{"chemblId":"CHEMBL85398","moleculeType":"Small molecule","molecularWeight":"117.13"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Biguanides (e.g., metformin) decrease hepatic glucose production and improve peripheral insulin sensitivity, while thiazolidinediones enhance insulin sensitivity in muscle and adipose tissue by activating PPAR-γ. Together, they address multiple pathophysiological defects in type 2 diabetes through synergistic glucose-lowering effects.","oneSentence":"This combination of biguanides and thiazolidinediones improves insulin sensitivity and reduces hepatic glucose production through complementary mechanisms in type 2 diabetes management.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:20.951Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05663515","phase":"","title":"A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-09-30","conditions":"Pancreatic Cancer","enrollment":24000},{"nctId":"NCT03499704","phase":"PHASE4","title":"A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy","status":"COMPLETED","sponsor":"Celltrion Pharm, Inc.","startDate":"2020-02-11","conditions":"Diabetes Mellitus, Type 2","enrollment":133},{"nctId":"NCT07472179","phase":"NA","title":"Effect of Pioglitazone vs Metformin on Clinical, Biochemical and Hormonal Parameters of Insulin Resistant PCOS","status":"COMPLETED","sponsor":"Mst.Sumyara Khatun","startDate":"2024-08-12","conditions":"PCOS(Insulin Resistant)","enrollment":60},{"nctId":"NCT04416269","phase":"PHASE4","title":"Oral Anti Diabetic Agents in the Hospital","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2020-08-07","conditions":"Diabetes Mellitus","enrollment":255},{"nctId":"NCT06851962","phase":"PHASE4","title":"Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2025-05-26","conditions":"Diabetes Mellitus Type 2","enrollment":504},{"nctId":"NCT07314684","phase":"PHASE4","title":"GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM","status":"RECRUITING","sponsor":"Federico II University","startDate":"2025-09-08","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":80},{"nctId":"NCT07057479","phase":"PHASE3","title":"Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-09","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":""},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT06446531","phase":"PHASE1","title":"Prevention of Progression of Prediabetes, Obesity and CV Risk","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2024-09-11","conditions":"Pre-Diabetes, Weight, Body, Cardiovascular Diseases","enrollment":64},{"nctId":"NCT01471808","phase":"PHASE4","title":"Effects of Different Early Intensive Therapies on Long-term β-cell Function","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2011-10","conditions":"Diabetes Mellitus, Type 2","enrollment":264},{"nctId":"NCT06972732","phase":"PHASE4","title":"A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes","status":"RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2025-06-11","conditions":"Type 2 Diabetes","enrollment":204},{"nctId":"NCT02969798","phase":"NA","title":"Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2014-01-01","conditions":"Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG)","enrollment":700},{"nctId":"NCT07083401","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics and Safety Between \"BR3006\" and Co-administration of \"BR3006A\", \"BR3006B\", and \"BR3006C\" in Healthy Adult Volunteers (Fed)","status":"RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2025-07-05","conditions":"Diabete Mellitus","enrollment":40},{"nctId":"NCT07083388","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics and Safety Between \"BR3006\" and Co-administration of \"BR3006A\", \"BR3006B\", and \"BR3006C\" in Healthy Adult Volunteers (Fasting)","status":"RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2025-07-03","conditions":"Diabetes Mellitus","enrollment":52},{"nctId":"NCT02879409","phase":"NA","title":"HbA1c Variability in Type II Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Cornell Medical College in Qatar","startDate":"2016-11","conditions":"Diabetes Mellitus Type 2","enrollment":150},{"nctId":"NCT06101667","phase":"NA","title":"Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO)","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2023-10-15","conditions":"Acute Ischemic Stroke, Basilar Artery Occlusion","enrollment":224},{"nctId":"NCT04114136","phase":"PHASE2","title":"Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies","status":"RECRUITING","sponsor":"Dan Zandberg","startDate":"2020-09-14","conditions":"Melanoma, NSCLC, Hepatocellular Carcinoma","enrollment":72},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT05394142","phase":"PHASE2","title":"A Clinical Trial to Evaluate the Efficacy, Tolerability, and Safety of a Fixed Dose Combination of Spironolactone, Pioglitazone & Metformin (SPIOMET) in Polycystic Ovary Syndrome (PCOS)","status":"RECRUITING","sponsor":"Fundació Sant Joan de Déu","startDate":"2022-05-24","conditions":"Polycystic Ovary Syndrome (PCOS)","enrollment":364},{"nctId":"NCT06243536","phase":"PHASE4","title":"The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients","status":"UNKNOWN","sponsor":"University Hospital Sestre Milosrdnice","startDate":"2024-02-01","conditions":"Type 2 Diabetes, Overweight, Disordered Eating Behaviors","enrollment":60},{"nctId":"NCT05942963","phase":"PHASE4","title":"Efficacy of Empagliflozin and Pioglitazone in Diabetic Patients With NAFLD","status":"UNKNOWN","sponsor":"Jinnah Postgraduate Medical Centre","startDate":"2023-10","conditions":"Non-Alcoholic Fatty Liver Disease, Type2diabetes","enrollment":240},{"nctId":"NCT04419337","phase":"PHASE2","title":"Pioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With Stroke","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2019-09-15","conditions":"Diabetes Mellitus, Stroke","enrollment":200},{"nctId":"NCT03871621","phase":"PHASE4","title":"Left Ventricular Functional Changes of Uncontrolled Diabetes by Dapagliflozin Treatment Trial","status":"COMPLETED","sponsor":"Mackay Memorial Hospital","startDate":"2019-04-01","conditions":"Type 2 Diabetes Mellitus","enrollment":76},{"nctId":"NCT05629806","phase":"PHASE3","title":"Effect of Acarbose and Mixture of Pioglitazone and Metformin in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2022-04-10","conditions":"Type 2 Diabetes, Blood Glucose Fluctuation","enrollment":50},{"nctId":"NCT05591235","phase":"PHASE3","title":"Effect of Metformin, Dapagliflozin, Combination of Metformin and Pioglitazone in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2022-11","conditions":"Type2diabetes, Insulin Resistance","enrollment":60},{"nctId":"NCT05565976","phase":"PHASE2, PHASE3","title":"Dapagliflozin Effect in Cognitive Impairment in Stroke Trial","status":"UNKNOWN","sponsor":"Jaime Daniel Mondragon","startDate":"2020-08-01","conditions":"Stroke, Ischemic, Mild Cognitive Impairment, Dementia, Vascular","enrollment":270},{"nctId":"NCT05521633","phase":"PHASE3","title":"Comparison of the Effects of Metformin and Pioglitazone on Liver Enzymes and Ultrasound Changes in Non-Diabetic Non-Alcoholic Fatty Liver","status":"COMPLETED","sponsor":"King Edward Medical University","startDate":"2019-06-06","conditions":"NAFLD","enrollment":96},{"nctId":"NCT05519813","phase":"PHASE4","title":"Effects of Pioglitazone Combined With Metformin on Gonadal and Metabolic Profiles in Chinese Nonobese PCOS Patients.","status":"UNKNOWN","sponsor":"Bing He","startDate":"2022-01-01","conditions":"Polycystic Ovary Syndrome","enrollment":60},{"nctId":"NCT03486964","phase":"","title":"Use of Incretins in Diabetic Patients","status":"COMPLETED","sponsor":"University of Pavia","startDate":"2018-03-27","conditions":"Diabetes Mellitus, Type 2","enrollment":2234},{"nctId":"NCT02787551","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-06","conditions":"Type 2 Diabetes Mellitus","enrollment":514},{"nctId":"NCT04867252","phase":"PHASE2","title":"Effects of Combined Resveratrol and Myo-inositol on Altered Metabolic, Endocrine Parameters and Perceived Stress in Patients With Polycystic Ovarian Syndrome","status":"COMPLETED","sponsor":"Khyber Medical University Peshawar","startDate":"2021-05-03","conditions":"PCOS","enrollment":88},{"nctId":"NCT00081328","phase":"PHASE3","title":"Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY)","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2004-05","conditions":"Diabetes Mellitus, Type II","enrollment":699},{"nctId":"NCT03566225","phase":"EARLY_PHASE1","title":"Pioglitazone Versus Metformin as First Treatment in Infertile Women With Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2018-01-30","conditions":"Pioglitazone","enrollment":400},{"nctId":"NCT00571519","phase":"PHASE3","title":"Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus","status":"TERMINATED","sponsor":"Daiichi Sankyo","startDate":"2007-11-14","conditions":"Type 2 Diabetes Mellitus","enrollment":94},{"nctId":"NCT04662866","phase":"PHASE2","title":"Effects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting Glucose","status":"UNKNOWN","sponsor":"Oslo University Hospital","startDate":"2021-02-10","conditions":"Impaired Glucose Tolerance, Insulin Sensitivity, Glucose Metabolism Disorders","enrollment":64},{"nctId":"NCT00510705","phase":"NA","title":"Chronic Inflammatory Activation in Fat Tissue: An Atherogenic Factor in Severe Coronary Artery Disease","status":"TERMINATED","sponsor":"University of Leipzig","startDate":"2007-07","conditions":"Severe Coronary Artery Disease, Obesity, Impaired Glucose Tolerance","enrollment":29},{"nctId":"NCT03452267","phase":"PHASE2, PHASE3","title":"Insulin Signaling in Skeletal Muscle","status":"WITHDRAWN","sponsor":"Wayne State University","startDate":"2019-09-01","conditions":"Insulin Sensitivity","enrollment":""},{"nctId":"NCT04392557","phase":"PHASE4","title":"Anti-inflammatory Status in DM2 Treated Patients","status":"UNKNOWN","sponsor":"University of Catanzaro","startDate":"2020-07-01","conditions":"Diabetes Mellitus, Type 2","enrollment":36},{"nctId":"NCT03117517","phase":"EARLY_PHASE1","title":"Treatment With Metformin and Combination of Metformin and Pioglitazone in Polycystic Ovarian Syndrome","status":"COMPLETED","sponsor":"Khyber Medical University Peshawar","startDate":"2017-03-20","conditions":"Polycystic Ovarian Syndrome","enrollment":106},{"nctId":"NCT04287387","phase":"PHASE4","title":"Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-03-02","conditions":"Type2 Diabetes Mellitus","enrollment":180},{"nctId":"NCT04113889","phase":"PHASE2","title":"Effects of Triple Drug Cocktail Therapy on Metabolic, Endocrine Alterations and Perceived Stress in Patients With Poly Cystic Ovary Syndrome","status":"COMPLETED","sponsor":"Khyber Medical University Peshawar","startDate":"2019-10-15","conditions":"PCOS","enrollment":147},{"nctId":"NCT02689843","phase":"EARLY_PHASE1","title":"Effects of Cyproterone Compound-spironolactone, Metformin and Pioglitazone on Inflammatory Markers in PCOS","status":"COMPLETED","sponsor":"Shiraz University of Medical Sciences","startDate":"2018-02-01","conditions":"Polycystic Ovary Syndrome","enrollment":90},{"nctId":"NCT04148183","phase":"PHASE2, PHASE3","title":"Effect of Metformin and Rosiglitazone Over no Diabetic With Metabolic Syndrome Patients.","status":"COMPLETED","sponsor":"J JESUS VENEGAS, MD","startDate":"2004-01-01","conditions":"Insulin Resistance","enrollment":30},{"nctId":"NCT02072096","phase":"PHASE4","title":"A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2014-02","conditions":"Diabetes Mellitus, Type 2","enrollment":192},{"nctId":"NCT00694759","phase":"NA","title":"Cortisol Regulation in Polycystic Ovary Syndrome (PCOS)","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2006-10","conditions":"Polycystic Ovary Syndrome","enrollment":37},{"nctId":"NCT02989649","phase":"","title":"Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice","status":"TERMINATED","sponsor":"Takeda","startDate":"2016-12-22","conditions":"Diabetes Mellitus, Type 2","enrollment":593},{"nctId":"NCT02188186","phase":"PHASE4","title":"Therapeutic Efficacy of Triple Combination in Drug-naïve Korean Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2014-07","conditions":"Type 2 Diabetes","enrollment":200},{"nctId":"NCT01894568","phase":"PHASE3","title":"A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-07","conditions":"Type 2 Diabetes Mellitus","enrollment":388},{"nctId":"NCT02954692","phase":"PHASE4","title":"A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-11-30","conditions":"Type 2 Diabetes Mellitus","enrollment":112},{"nctId":"NCT03757923","phase":"PHASE1, PHASE2","title":"Comparison of Metformin and Pioglitazone in Regulating Menstrual Irregularities and Hyperandrogenism","status":"UNKNOWN","sponsor":"Dow University of Health Sciences","startDate":"2018-06-18","conditions":"Menstrual Irregularities, Hyperandrogenism","enrollment":110},{"nctId":"NCT01972724","phase":"PHASE4","title":"Efficacy of Pioglitazone in Participants With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy","status":"COMPLETED","sponsor":"Takeda","startDate":"2013-12-16","conditions":"Type II Diabetes Mellitus","enrollment":114},{"nctId":"NCT01697592","phase":"PHASE3","title":"Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-24","conditions":"Type 2 Diabetes Mellitus","enrollment":585},{"nctId":"NCT01217073","phase":"PHASE2","title":"A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-10-08","conditions":"Type 2 Diabetes Mellitus","enrollment":685},{"nctId":"NCT00427154","phase":"PHASE3","title":"Effect of Inhaled Pre-prandial Human Insulin on Blood Glucose Control in Type 2 Diabetes","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2007-01-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":227},{"nctId":"NCT00577590","phase":"NA","title":"Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2003-10","conditions":"Diabetes Mellitus, Type II","enrollment":78},{"nctId":"NCT00679939","phase":"PHASE4","title":"Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes Drugs And How They Affect Bone Health","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-04-21","conditions":"Diabetes Mellitus, Type 2","enrollment":226},{"nctId":"NCT00499707","phase":"PHASE3","title":"Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-10-08","conditions":"Diabetes Mellitus, Type 2","enrollment":453},{"nctId":"NCT00232583","phase":"NA","title":"Preservation of Beta-cell Function in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2003-11","conditions":"Type 2 Diabetes Mellitus","enrollment":58},{"nctId":"NCT02733679","phase":"PHASE4","title":"Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone","status":"COMPLETED","sponsor":"NHS Tayside","startDate":"2016-09-29","conditions":"Ataxia-Telangiectasia","enrollment":27},{"nctId":"NCT00279045","phase":"PHASE3","title":"Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2000-01-03","conditions":"Diabetes Mellitus, Type 2","enrollment":4426},{"nctId":"NCT00780715","phase":"PHASE4","title":"Response To Oral Agents in Diabetes (ROAD)- Pilot Study","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2008-12","conditions":"Diabetes Mellitus, Type 2","enrollment":29},{"nctId":"NCT01095666","phase":"PHASE3","title":"A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-06","conditions":"Type 2 Diabetes","enrollment":1484},{"nctId":"NCT02875821","phase":"PHASE4","title":"Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2016-04-26","conditions":"Type 2 Diabetes With Non-alcoholic Fatty Liver (NAFLD)","enrollment":44},{"nctId":"NCT03196362","phase":"PHASE4","title":"Impacts of PIO/MET Following Short-term Intensive Insulin Treatment in Newly Diagnosed Type 2 Diabetes","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-12-01","conditions":"Type 2 Diabetes Mellitus","enrollment":50},{"nctId":"NCT00532935","phase":"PHASE3","title":"MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-01-26","conditions":"Type 2 Diabetes Mellitus","enrollment":517},{"nctId":"NCT01076075","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-03","conditions":"Type 2 Diabetes Mellitus","enrollment":427},{"nctId":"NCT01357135","phase":"","title":"An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®/Xelevia®, MK-0431-201)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-07-15","conditions":"Type 2 Diabetes Mellitus","enrollment":3453},{"nctId":"NCT00885352","phase":"PHASE3","title":"Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04-15","conditions":"Type 2 Diabetes Mellitus","enrollment":313},{"nctId":"NCT00722371","phase":"PHASE3","title":"MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-09-05","conditions":"Type 2 Diabetes Mellitus","enrollment":1615},{"nctId":"NCT01028391","phase":"PHASE3","title":"30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-09-01","conditions":"Type 2 Diabetes Mellitus","enrollment":317},{"nctId":"NCT00541450","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-01-15","conditions":"Type 2 Diabetes Mellitus","enrollment":492},{"nctId":"NCT00350779","phase":"PHASE3","title":"Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-06-12","conditions":"Type 2 Diabetes Mellitus","enrollment":262},{"nctId":"NCT00086515","phase":"PHASE3","title":"Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-06-30","conditions":"Diabetes Mellitus, Type II","enrollment":701},{"nctId":"NCT01777282","phase":"PHASE3","title":"A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-02-23","conditions":"Diabetes Mellitus","enrollment":374},{"nctId":"NCT00032487","phase":"PHASE3","title":"Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2000-12-01","conditions":"Type 2 Diabetes Mellitus","enrollment":1791},{"nctId":"NCT00379769","phase":"PHASE3","title":"RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2001-04","conditions":"Diabetes Mellitus, Type 2","enrollment":4447},{"nctId":"NCT00362440","phase":"PHASE2","title":"Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2006-08","conditions":"HIV Lipodystrophy","enrollment":9},{"nctId":"NCT00348712","phase":"PHASE3","title":"Efficacy and Safety of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes","status":"TERMINATED","sponsor":"Novo Nordisk A/S","startDate":"2006-10-30","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":301},{"nctId":"NCT00333151","phase":"PHASE3","title":"Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":576},{"nctId":"NCT00097279","phase":"PHASE3","title":"Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-08","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":230},{"nctId":"NCT00598793","phase":"PHASE3","title":"Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2002-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":242},{"nctId":"NCT00839527","phase":"PHASE3","title":"A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02","conditions":"Diabetes Mellitus, Type 2","enrollment":685},{"nctId":"NCT00763815","phase":"PHASE3","title":"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-09","conditions":"Diabetes Mellitus Type 2","enrollment":484},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT02024971","phase":"","title":"Special Drug Use Surveillance of Pioglitazone/Metformin Hydrochloride Combination Tablets Survey on Long-term Use for Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-07","conditions":"Type 2 Diabetes Mellitus","enrollment":1103},{"nctId":"NCT02003014","phase":"","title":"Pioglitazone Tablets Special Drug Use Surveillance \"Combined Use of Biguanides / Long-term Treatment\"","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-02","conditions":"Type 2 Diabetes Mellitus","enrollment":899},{"nctId":"NCT02476760","phase":"","title":"Incretin-based Drugs and Acute Pancreatitis","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":1417914},{"nctId":"NCT00975286","phase":"PHASE3","title":"24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-10","conditions":"Type 2 Diabetes Mellitus","enrollment":446},{"nctId":"NCT00744367","phase":"PHASE3","title":"A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-10","conditions":"Diabetes Mellitus Type 2","enrollment":326},{"nctId":"NCT01612858","phase":"PHASE4","title":"Metabolic Abnormalities in HIV-infected Persons","status":"COMPLETED","sponsor":"Tufts Medical Center","startDate":"2011-06","conditions":"Lipodystrophy, HIV Infection","enrollment":20},{"nctId":"NCT00437970","phase":"PHASE4","title":"Medication in Early Diabetes (MED) Study","status":"WITHDRAWN","sponsor":"Menzies School of Health Research","startDate":"2008-04","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT02456428","phase":"","title":"Incretin-based Drugs and the Risk of Heart Failure","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Type 2 Diabetes Mellitus","enrollment":1499650},{"nctId":"NCT02475499","phase":"","title":"Incretin-based Drugs and Pancreatic Cancer","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":886172},{"nctId":"NCT00933309","phase":"PHASE1","title":"The Impact of Obesity and Obesity Treatments on Breast Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-07","conditions":"Breast Cancer","enrollment":25},{"nctId":"NCT00006305","phase":"PHASE3","title":"Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2000-09","conditions":"Coronary Disease, Cardiovascular Diseases, Heart Diseases","enrollment":2368},{"nctId":"NCT00086502","phase":"PHASE3","title":"Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-06","conditions":"Diabetes Mellitus, Type 2","enrollment":353},{"nctId":"NCT00486187","phase":"NA","title":"Effects of ROSIglitazone on Inflammatory Markers and Adipokines in Diabetic Patients Using an Angiotensin Receptor Blocker (TELmisartan) - The ROSITEL Study","status":"COMPLETED","sponsor":"Dr. Milan Gupta","startDate":"2006-04","conditions":"Type 2 Diabetes Mellitus","enrollment":103},{"nctId":"NCT00219440","phase":"PHASE4","title":"A Portion-controlled Diet Will Prevent Weight Gain in Diabetics Treated With ACTOS","status":"COMPLETED","sponsor":"Pennington Biomedical Research Center","startDate":"2003-02","conditions":"Diabetes Mellitus","enrollment":60},{"nctId":"NCT00815399","phase":"PHASE4","title":"Pioglitazone Versus Metformin in Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2007-10","conditions":"Type 2 Diabetes","enrollment":150},{"nctId":"NCT02526615","phase":"PHASE4","title":"Effects of Rosiglitazone and Metformin on Metabolism in Type 2 Diabetes","status":"COMPLETED","sponsor":"Turku University Hospital","startDate":"2000-10","conditions":"Insulin Sensitivity, Type 2 Diabetes","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Biguanides, thiazolidinediones","genericName":"Biguanides, thiazolidinediones","companyName":"University of Pittsburgh","companyId":"university-of-pittsburgh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination of biguanides and thiazolidinediones improves insulin sensitivity and reduces hepatic glucose production through complementary mechanisms in type 2 diabetes management. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}